Avacta Group Share News (AVCT)
AVCT Share
AVCT Share
AVCT Share
AVCT Share
AVCT
AVCT Share
AVCT Level 2
AVCT Live
AVCT Broker
AVCT Directors
AVCT Financial
AVCT
AVCT Short
AVCT
Last checked at -
Thu, 23rd Aug 2018 14:20
LONDON (Alliance News) - Avacta Group PLC on Thursday said Lombard Odier Asset Management Europe Ltd reduced its holding in the biotechnology company.
In a transaction on Tuesday, Lombard Odier cut its stake to 4.6%, having previously held a 9.7% interest.
Shares in Avacta were trading 8.8% higher on Thursday at 3.70 pence each.
Avacta Group Reports Widened Loss Amid Higher Operating Expenses
Read moreUK TRADING UPDATE SUMMARY: Avacta, Genedrive Progress With Virus Tests
Read more
(Sharecast News) - Biotherapeutics developer Avacta has entered into a collaboration agreement with American firm Adeptrix to develop a high throughput Covid-19 antigen test using its proprietary bead-assisted mass spectrometry (BAMS) platform.
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read moreUK TRADING UPDATE SUMMARY: BATM Gets EUR29 Million Ventilator Order
Read more(Sharecast News) - Avacta Group said on Wednesday that, in four weeks and "well ahead" of schedule, it had successfully generated multiple 'Affimer' reagents that bound the SARS-COV-2 viral antigen as part of the collaboration with Cytiva - formerly GE Healthcare Life Sciences - to develop an Affimer-based rapid test for the Covid-19 coronavirus infection.
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read moreAvacta To Co-Develop Test That Can Diagnose Covid-19 In Minutes
Read moreAvacta Raises More-Than-Expected GBP3.8 Million In Share Placing
Read more(Sharecast News) - Biotherapeutics company Avacta Group announced on Monday that, in response to "substantial" institutional interest, it has conditionally raised gross proceeds of ?3.75m under a placing, through the issue of 20,833,333 new ordinary shares at a price of 18p each.
Read moreAvacta Announces GBP2 Million Subscription With Two Subscribers
Read moreAvacta Inks Cell And Gene Therapy Deal With Joint Venture AffyXell
Read more(Sharecast News) - Biotherapeutics and reagents developer Avacta Group announced on Monday that it has signed a collaboration and license agreement with AffyXell Therapeutics - the recently-established joint venture with Daewoong Pharmaceutical - to develop Affimer proteins to be used by AffyXell for the generation of new cell and gene therapies.
Read moreAvacta Demonstrates Initial Proof Of Concept For Cancer Drug TMAC
Read moreAffimer Unit Performance Helps Avacta Revenue Beat Market Forecasts
Read more
Last checked at